Axcella Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Axcella is a clinical-stage biotechnology company focused on treating complex diseases through compositions of endogenous metabolic modulators (EMMs). Its therapeutics combine EMMs and derivatives in specific combinations and ratios to influence multiple biological pathways, with the aim of improving cellular energetics and restoring homeostasis. Its pipeline includes lead candidates in Phase 2 for reducing the risk of overt hepatic encephalopathy recurrence, the treatment of Long Covid, and the treatment of non-alcoholic steatohepatitis (NASH). The company is based in Cambridge, Massachusetts, and operates as a relatively small organization. It pursues a development model that allows evaluation of EMM compositions through non-IND clinical studies or IND clinical trials. In August 2023, Axcella announced a patent grant related to its Long Covid fatigue program.